Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 20;5(1):fcad011. doi: 10.1093/braincomms/fcad011

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

CSF concentrations of CCL3, IL-12B, IL-8 and CXL10 in healthy controls, untreated patients and relapsing-remitting MS patients treated with first- and second-line treatment. Treatment effects on baseline CCL3, IL-12B, IL-8 and CXCL10 were estimated using linear regression models adjusted for age and sex. Pairwise comparisons between treatments were estimated using the marginal means from the linear regression model. In general, patients with first-line treatment had higher concentrations than untreated patients and patients treated with second-line treatment. Each datapoint represents a patient’s protein NPX value. NS = not significant, *P < 0.05, **P < 0.01, ***P < 0.001.